NO2020018I1 - Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof - Google Patents

Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof

Info

Publication number
NO2020018I1
NO2020018I1 NO2020018C NO2020018C NO2020018I1 NO 2020018 I1 NO2020018 I1 NO 2020018I1 NO 2020018 C NO2020018 C NO 2020018C NO 2020018 C NO2020018 C NO 2020018C NO 2020018 I1 NO2020018 I1 NO 2020018I1
Authority
NO
Norway
Prior art keywords
darolutamide
ester
optionally
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO2020018C
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383475&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2020018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of NO2020018I1 publication Critical patent/NO2020018I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
NO2020018C 2009-10-27 2020-06-17 Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof NO2020018I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515909P 2009-10-27 2009-10-27
PCT/FI2010/000065 WO2011051540A1 (en) 2009-10-27 2010-10-27 Androgen receptor modulating compounds

Publications (1)

Publication Number Publication Date
NO2020018I1 true NO2020018I1 (no) 2020-06-17

Family

ID=43383475

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2020018C NO2020018I1 (no) 2009-10-27 2020-06-17 Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof

Country Status (36)

Country Link
US (5) US8975254B2 (no)
EP (5) EP2754656A1 (no)
JP (1) JP5763083B2 (no)
KR (2) KR101654529B1 (no)
CN (2) CN105061313B (no)
AR (1) AR078793A1 (no)
AU (1) AU2010311299C1 (no)
BR (1) BR112012008823B8 (no)
CA (1) CA2777896C (no)
CL (1) CL2012000772A1 (no)
CO (1) CO6531494A2 (no)
CY (2) CY2020010I2 (no)
DK (3) DK2493858T3 (no)
EA (1) EA021170B1 (no)
ES (3) ES2877248T3 (no)
GE (1) GEP20166472B (no)
HK (1) HK1173442A1 (no)
HR (3) HRP20140919T1 (no)
HU (2) HUE055528T2 (no)
IL (2) IL218586A (no)
LT (3) LT3369732T (no)
LU (1) LUC00154I2 (no)
MX (1) MX2012004867A (no)
MY (1) MY159924A (no)
NL (1) NL301041I2 (no)
NO (1) NO2020018I1 (no)
NZ (1) NZ598747A (no)
PE (1) PE20121058A1 (no)
PL (3) PL3369732T3 (no)
PT (3) PT2493858E (no)
RS (3) RS57592B1 (no)
SI (3) SI2493858T1 (no)
SM (1) SMT201400138B (no)
UA (1) UA109535C2 (no)
WO (1) WO2011051540A1 (no)
ZA (1) ZA201202655B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007500A2 (de) * 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2699561B1 (en) * 2011-04-21 2015-06-03 Orion Corporation Androgen receptor modulating carboxamides
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
KR102057357B1 (ko) * 2012-03-15 2019-12-18 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
KR20140138931A (ko) * 2012-03-23 2014-12-04 니혼노야쿠가부시키가이샤 티아졸카르복사미드 유도체 및 그 사용 방법
EP2862855A4 (en) 2012-06-15 2015-11-18 Taisho Pharmaceutical Co Ltd HETERO-AROMATIC ALKYL RING DERIVATIVE WITH BRANCHED CHAINS
WO2014031784A1 (en) 2012-08-23 2014-02-27 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CN102952095A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法
CN114716426A (zh) 2013-08-21 2022-07-08 詹森生物制药有限公司 抗病毒化合物
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
MX2017009454A (es) 2015-01-20 2017-10-20 Arvinas Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos.
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
RS63477B1 (sr) * 2015-01-30 2022-08-31 Orion Corp Derivat karboksamida i njegovi dijastereoizomeri u stabilnom kristalnom obliku
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EP3280710B1 (en) * 2015-04-09 2020-02-26 Orion Corporation Process for the preparation of androgen receptor antagonists and intermediates thereof
AU2016264220A1 (en) * 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors
JP6630844B2 (ja) * 2015-12-07 2020-01-15 蘇州信諾維医薬科技有限公司Ｓｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ５員複素環式アミド系ｗｎｔ経路阻害剤
CN107286094A (zh) * 2016-04-12 2017-10-24 常州爱诺新睿医药技术有限公司 一种bay-1841788与药用辅料的固体分散体及其制备方法
ES2869882T3 (es) * 2016-08-26 2021-10-26 Bayer Consumer Care Ag Formas cristalinas de un antagonista del receptor de andrógenos, procedimiento de preparación y uso de las mismas
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
US11168058B2 (en) 2017-03-07 2021-11-09 Orion Corporation Manufacture of a crystalline pharmaceutical product
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
WO2019028689A1 (zh) 2017-08-09 2019-02-14 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
EP3759076A1 (en) 2018-02-27 2021-01-06 Sandoz AG Crystalline form ii of darolutamide
EP3836933A4 (en) * 2018-08-13 2022-08-10 National Centre for Biological Sciences-TIFR INHIBITORS AGAINST HIV-1-NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTIONS
US20210386826A1 (en) 2018-11-05 2021-12-16 Pfizer Inc. Combination for Treating Cancer
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
CN111620821B (zh) * 2019-02-27 2022-02-11 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
KR20220028097A (ko) 2019-07-02 2022-03-08 오리온 코포레이션 다롤루타미드의 약제학적 조성물
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
EP4009969A1 (en) 2019-08-08 2022-06-15 Laekna Limited Method of treating cancer
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
KR20230009958A (ko) 2020-05-11 2023-01-17 오리온 코포레이션 안드로겐 수용체 길항제 및 이의 중간체의 제조 방법
IL300581A (en) 2020-08-13 2023-04-01 Pfizer Combined treatment
CN111978534B (zh) * 2020-09-07 2022-05-31 陕西师范大学 一种含苯并咪唑液晶基元的侧链型液晶离聚物及其制备方法
WO2022200982A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
CN113527208A (zh) * 2021-08-31 2021-10-22 江西金丰药业有限公司 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法
CN113861115A (zh) * 2021-09-10 2021-12-31 浙江师范大学 一种吡唑酰胺类衍生物及合成方法和应用
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
FR2656609B1 (fr) 1989-12-28 1992-03-27 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
US5578550A (en) 1993-10-08 1996-11-26 American Cyanamid Company Herbicidal oxadiazole carbonamide compounds
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
CA2345146C (en) 1998-09-22 2010-02-23 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivative
IL161155A0 (en) 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
WO2003057669A1 (fr) 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
CA2471880A1 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
EP1465872A1 (en) * 2001-12-28 2004-10-13 Bayer Pharmaceuticals Corporation 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
TW200406386A (en) * 2002-06-07 2004-05-01 Novartis Ag Organic compounds
WO2004013130A1 (en) * 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004111012A1 (ja) 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体
EP1663953A1 (en) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
JP4989227B2 (ja) 2004-09-09 2012-08-01 中外製薬株式会社 新規イミダゾリジン誘導体およびその用途
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
EP1710237A1 (en) * 2005-04-08 2006-10-11 Bayer CropScience S.A. New heterocyclylethylbenzamide derivatives
MX346924B (es) 2005-05-13 2017-04-05 Univ California Compuestos de diarilhidantoina.
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
AR057656A1 (es) * 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2006311914C1 (en) * 2005-11-03 2013-10-24 Chembridge Corporation Heterocyclic compounds as tyrosine kinase modulators
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008062878A1 (fr) 2006-11-22 2008-05-29 Nihon Nohyaku Co., Ltd. Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
MX2010002266A (es) 2007-08-30 2010-03-25 Takeda Pharmaceutical Derivados de pirazol sustituidos.
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
TW200944506A (en) 2008-03-26 2009-11-01 Takeda Pharmaceutical Substituted pyrazole derivatives and use thereof
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives

Also Published As

Publication number Publication date
ES2877248T3 (es) 2021-11-16
HUE039390T2 (hu) 2018-12-28
HRP20211180T1 (hr) 2021-10-15
US10118933B2 (en) 2018-11-06
RS57592B1 (sr) 2018-11-30
EP3056485B1 (en) 2018-05-09
SI3369732T1 (sl) 2021-08-31
US20190100536A1 (en) 2019-04-04
PT3056485T (pt) 2018-07-31
NL301041I2 (nl) 2020-09-14
PL3056485T3 (pl) 2018-12-31
WO2011051540A9 (en) 2011-06-23
SMT201400138B (it) 2014-11-10
GEP20166472B (en) 2016-05-10
CL2012000772A1 (es) 2012-08-24
IL238044A (en) 2016-07-31
US10711013B2 (en) 2020-07-14
EP2493858A1 (en) 2012-09-05
CA2777896C (en) 2017-05-23
WO2011051540A8 (en) 2012-04-19
US11046713B2 (en) 2021-06-29
HUE055528T2 (hu) 2021-12-28
LT3056485T (lt) 2018-07-25
KR101670299B1 (ko) 2016-10-28
CY2020010I1 (el) 2020-11-25
US9657003B2 (en) 2017-05-23
PE20121058A1 (es) 2012-08-18
RS62123B1 (sr) 2021-08-31
MX2012004867A (es) 2012-06-08
JP2013508447A (ja) 2013-03-07
NZ598747A (en) 2013-06-28
KR101654529B1 (ko) 2016-09-06
IL218586A (en) 2015-10-29
PL2493858T3 (pl) 2015-01-30
LUC00154I2 (no) 2021-02-17
EP3369732A1 (en) 2018-09-05
SI2493858T1 (sl) 2014-10-30
JP5763083B2 (ja) 2015-08-12
LTC2493858I2 (lt) 2022-03-25
CY1124429T1 (el) 2022-07-22
AU2010311299A1 (en) 2012-04-12
DK3369732T3 (da) 2021-07-26
BR112012008823A2 (pt) 2019-02-19
CO6531494A2 (es) 2012-09-28
HK1173442A1 (zh) 2013-05-16
EP3885340A1 (en) 2021-09-29
CN105061313B (zh) 2017-07-18
EA201270597A1 (ru) 2012-10-30
CN102596910A (zh) 2012-07-18
PL3369732T3 (pl) 2021-12-06
EP2493858B1 (en) 2014-07-02
EA021170B1 (ru) 2015-04-30
HRP20140919T1 (hr) 2014-11-21
EP3056485A1 (en) 2016-08-17
BR112012008823B8 (pt) 2021-05-25
EP2754656A1 (en) 2014-07-16
LUC00154I1 (no) 2020-05-19
DK3056485T3 (en) 2018-07-30
CN105061313A (zh) 2015-11-18
CY2020010I2 (el) 2020-11-25
CA2777896A1 (en) 2011-05-05
KR20160105927A (ko) 2016-09-07
PT2493858E (pt) 2014-09-03
ES2678073T3 (es) 2018-08-08
AR078793A1 (es) 2011-12-07
CN102596910B (zh) 2015-11-25
US20150203479A1 (en) 2015-07-23
KR20120102057A (ko) 2012-09-17
IL218586A0 (en) 2012-05-31
HRP20181229T1 (hr) 2018-10-05
RS53469B (en) 2014-12-31
US8975254B2 (en) 2015-03-10
BR112012008823B1 (pt) 2021-01-12
DK2493858T3 (da) 2014-09-08
ES2486263T3 (es) 2014-08-18
AU2010311299C1 (en) 2023-02-02
MY159924A (en) 2017-02-15
US20200299307A1 (en) 2020-09-24
EP3369732B1 (en) 2021-05-26
US20120225867A1 (en) 2012-09-06
WO2011051540A1 (en) 2011-05-05
SI3056485T1 (en) 2018-08-31
US20170260206A1 (en) 2017-09-14
LTPA2020514I1 (lt) 2020-07-27
UA109535C2 (uk) 2015-09-10
LT3369732T (lt) 2021-06-25
PT3369732T (pt) 2021-07-06
AU2010311299A8 (en) 2012-06-14
AU2010311299B2 (en) 2014-07-17
ZA201202655B (en) 2012-12-27

Similar Documents

Publication Publication Date Title
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2019042I1 (no) Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2023017I1 (no) Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate
NO2020047I1 (no) Remdesivir eller et farmasøytisk akseptabelt salt eller ester derav
FIC20200039I1 (fi) Kefiderokoli valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2021040I1 (no) glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC
NO2017059I1 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2021039I1 (no) pibrentasvir or a pharmaceutically acceptable salt thereof - forlenget SPC
NL300995I2 (nl) Combinatie van glycopyrronium, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder glycopyrronium bromide, en formoterol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of ester, in het bijzonder formoterol fumaraat dihydraat
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
NO2015014I1 (no) Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav
NO2017024I1 (no) Elosulfase alfa eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2015012I1 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
NO2019010I1 (no) Eravasyklin eller farmasøytisk akseptable salter derav
BRPI1012004A2 (pt) "forma farmacêutica"
NO2023002I1 (no) Lasmiditan or a pharmaceutically acceptable salt thereof
FR2957244B1 (fr) Implant d'arthrodese